Marking the tempo for myogenesis: Pax7 and the regulation of muscle stem cell fate decisions

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 5, 2012, Pages 1013-1025

  Olguín, Hugo C ^a   Pisconti, Addolorata ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

MyoD; Pan genes; Pax7; Satellite cells

Indexed keywords

NOTCH RECEPTOR; SYNDECAN; TRANSCRIPTION FACTOR PAX7; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; GENE EXPRESSION REGULATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; MOUSE; MUSCLE DEVELOPMENT; MYOBLAST; PHYSIOLOGY; PROTEIN PROCESSING; RAT; REVIEW; SKELETAL MUSCLE; SKELETAL MUSCLE SATELLITE CELL; WNT SIGNALING PATHWAY;

ANIMALS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MICE; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; MYOBLASTS; PAX7 TRANSCRIPTION FACTOR; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RECEPTORS, NOTCH; SATELLITE CELLS, SKELETAL MUSCLE; SYNDECANS; TGF-BETA SUPERFAMILY PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; WNT SIGNALING PATHWAY;

EID: 84860335527     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01348.x     Document Type: Review

References (164)

1. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961; 9: 493-5.
2. Kuang S, Rudnicki MA. The emerging biology of satellite cells and their therapeutic potential. Trends Mol Med. 2008; 14: 82-91.
3. Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol. 2001; 91: 534-51.
4. Schultz E, McCormick KM. Skeletal muscle satellite cells. Rev Physiol Biochem Pharmacol. 1994; 123: 213-57.
5. Schultz E, Gibson MC, Champion T. Satellite cells are mitotically quiescent in mature mouse muscle: an EM and radioautographic study. J Exp Zool. 1978; 206: 451-6.
6. Cornelison DD, Wold BJ. Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev Biol. 1997; 191: 270-83.
7. Ciciliot S, Schiaffino S. Regeneration of mammalian skeletal muscle. Basic mechanisms and clinical implications. Curr Pharm Des. 2010; 16: 906-14.
8. Chargé SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev. 2004; 84: 209-38.
9. Shea KL, Xiang W, Laporta VS, et al. Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration. Cell Stem Cell. 2010; 6: 117-29.
10. Angello JC, Hauschka SD. Skeletal muscle satellite cells: timelapse videomicroscopic evidence that renewal is stochastic. BAM. 1996; 6: 491-502.
11. Baroffio A, Hamann M, Bernheim L, et al. Identification of self-renewing myoblasts in the progeny of single human muscle satellite cells. Differentiation. 1996; 60: 47-57.
12. Collins CA, Olsen I, Zammit PS, et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell. 2005; 122: 289-301.
13. Olguin HC, Olwin BB. Pax-7 up-regulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for self-renewal. Dev Biol. 2004; 275: 375-88.
14. Schultz E, Jaryszak DL, Gibson MC, et al. Absence of exogenous satellite cell contribution to regeneration of frozen skeletal muscle. J Muscle Res Cell Motil. 1986; 7: 361-7.
15. Zammit PS, Golding JP, Nagata Y, et al. Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? J Cell Biol. 2004; 166: 347-57.
16. Kuang S, Kuroda K, Le Grand F, et al. Asymmetric self-renewal and commitment of satellite stem cells in muscle. Cell. 2007; 129: 999-1010.
17. McFarlane C, Hennebry A, Thomas M, et al. Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp Cell Res. 2008; 314: 317-29.
18. Sacco A, Doyonnas R, Kraft P, et al. Self-renewal and expansion of single transplanted muscle stem cells. Nature. 2008; 456: 502-6.
19. Rudnicki MA, Le Grand F, McKinnell I, et al. The molecular regulation of muscle stem cell function. Cold Spring Harb Symp Quant Biol. 2008; 73: 323-31.
20. Peault B, Rudnicki M, Torrente Y, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther. 2007; 15: 867-77.
21. Shi X, Garry DJ. Muscle stem cells in development, regeneration, and disease. Genes Dev. 2006; 20: 1692-708.
22. Cornelison DD, Filla MS, Stanley HM, et al. Syndecan-3 and syndecan-4 specifically mark skeletal muscle satellite cells and are implicated in satellite cell maintenance and muscle regeneration. Dev Biol. 2001; 239: 79-94.
23. Fukada S, Uezumi A, Ikemoto M, et al. Molecular signature of quiescent satellite cells in adult skeletal muscle. Stem Cells. 2007; 25: 2448-59.
24. Mousavi K, Jasmin BJ. BDNF is expressed in skeletal muscle satellite cells and inhibits myogenic differentiation. J Neurosci. 2006; 26: 5739-49.
25. Schmidt K, Glaser G, Wernig A, et al. Sox8 is a specific marker for muscle satellite cells and inhibits myogenesis. J Biol Chem. 2003; 278: 29769-75.
26. Seale P, Sabourin LA, Girgis-Gabardo A, et al. Pax7 is required for the specification of myogenic satellite cells. Cell. 2000; 102: 777-86.
27. Kuang S, Chargé SB, Seale P, et al. Distinct roles for Pax7 and Pax3 in adult regenerative myogenesis. J Cell Biol. 2006; 172: 103-13.
28. Relaix F, Montarras D, Zaffran S, et al. Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J Cell Biol. 2006; 172: 91-102.
29. Olguin HC, Yang Z, Tapscott SJ, et al. Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination. J Cell Biol. 2007; 177: 769-79.
30. McKinnell IW, Ishibashi J, Le Grand F, et al. Pax7 activates myogenic genes by recruitment of a histone methyltransferase complex. Nat Cell Biol. 2008; 10: 77-84.
31. Collins CA, Gnocchi VF, White RB, et al. Integrated functions of Pax3 and Pax7 in the regulation of proliferation, cell size and myogenic differentiation. PLoS One. 2009; doi: 10.1371/journal.pone.0004475.
32. Lepper C, Conway SJ, Fan CM. Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements. Nature. 2009; 460: 627-31.
33. Buckingham M, Relaix F. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu Rev Cell Dev Biol. 2007; 23: 645-73.
34. Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 2002; 18: 41-7.
35. Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer. 2006; 6: 52-62.
36. Lang D, Powell SK, Plummer RS, et al. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol. 2007; 73: 1-14.
37. Wang Q, Fang WH, Krupinski J, et al. Pax genes in embryogenesis and oncogenesis. J Cell Mol Med. 2008; 12: 2281-94.
38. Bober E, Franz T, Arnold HH, et al. Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. Development. 1994; 120: 603-12.
39. Goulding M, Lumsden A, Paquette AJ. Regulation of Pax-3 expression in the dermomyotome and its role in muscle development. Development. 1994; 120: 957-71.
40. Tajbakhsh S, Rocancourt D, Cossu G, et al. Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell. 1997; 89: 127-38.
41. Ben-Yair R, Kalcheim C. Lineage analysis of the avian dermomyotome sheet reveals the existence of single cells with both dermal and muscle progenitor fates. Development. 2005; 132: 689-701.
42. Gros J, Manceau M, Thomé V, et al. A common somitic origin for embryonic muscle progenitors and satellite cells. Nature. 2005; 435: 954-8.
43. Kassar-Duchossoy L, Giacone E, Gayraud-Morel B, et al. Pax3/Pax7 mark a novel population of primitive myogenic cells during development. Genes Dev. 2005; 19: 1426-31.
44. Relaix F, Rocancourt D, Mansouri A, et al. A Pax3/Pax7-dependent population of skeletal muscle progenitor cells. Nature. 2005; 435: 948-53.
45. LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell. 2002; 111: 589-601.
46. Collins CA, Zammit PS, Ruiz AP, et al. A population of myogenic stem cells that survives skeletal muscle aging. Stem Cells. 2007; 25: 885-94.
47. Wang J, Conboy I. Embryonic versus. adult myogenesis: challenging the 'regeneration recapitulates development' paradigm. J Mol Cell Biol. 2010; 2: 1-4.
48. Reimann J, Brimah K, Schröder R, et al. Pax7 distribution in human skeletal muscle biopsies and myogenic tissue cultures. Cell Tissue Res. 2004; 315: 233-42.
49. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987; 51: 987-1000.
50. Weintraub H, Tapscott SJ, Davis RL, et al. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci USA. 1989; 86: 5434-8.
51. Zammit PS, Relaix F, Nagata Y, et al. Pax7 and myogenic progression in skeletal muscle satellite cells. J Cell Sci. 2006; 119: 1824-32.
52. Kumar D, Shadrach JL, Wagers AJ, et al. Id3 is a direct transcriptional target of Pax7 in quiescent satellite cells. Mol Biol Cell. 2009; 20: 3170-7.
53. Epstein JA, Lam P, Jepeal L, et al. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem. 1995; 270: 11719-22.
54. Chen Y, Lin G, Slack JM. Control of muscle regeneration in the Xenopus tadpole tail by Pax7. Development. 2006; 133: 2303-13.
55. Mitchell KJ, Pannérec A, Cadot B, et al. Identification and characterization of a non-satellite cell muscle resident progenitor during postnatal development. Nat Cell Biol. 2010; 12: 257-66.
56. + stem cells from injured muscle. PLoS Biol. 2004; 2: 664-72.
57. Potterf SB, Furumura M, Dunn KJ, et al. Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3. Hum Genet. 2000; 107: 1-6.
58. Lang D, Lu MM, Huang L, et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature. 2005; 433: 884-7.
59. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001; 20: 5736-46.
60. Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 1997; 94: 8047-51.
61. Fredericks WJ, Galili N, Mukhopadhyay S, et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol. 1995; 15: 1522-35.
62. Bennicelli JL, Fredericks WJ, Wilson RB, et al. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene. 1995; 11: 119-30.
63. Bennicelli JL, Edwards RH, Barr FG. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 1996; 93: 5455-9.
64. Davicioni E, Finckenstein FG, Shahbazian V, et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 2006; 66: 6936-46.
65. Cao L, Yu Y, Bilke S, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010; 70: 6497-508.
66. Graf Finckenstein F, Shahbazian V, Davicioni E, et al. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. Oncogene. 2008; 27: 2004-14.
67. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA. 1999; 96: 13264-9.
68. Olguín HC, Patzlaf NE, Olwin BB. PAX7-FKHR transcriptional activity is enhanced by transcriptionally repressed MyoD. J Cell Biochem. 2011; 112: 1410-17.
69. Kim J, Lo L, Dormand E, et al. SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells. Neuron. 2003; 38: 17-31.
70. Nutt SL, Heavey B, Rolink AG, et al. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature. 1999; 401: 556-62.
71. Mikkola I, Heavey B, Horcher M, et al. Reversion of B cell commitment upon loss of Pax5 expression. Science. 2002; 297: 110-13.
72. Marquardt T, Ashery-Padan R, Andrejewski N, et al. Pax6 is required for the multipotent state of retinal progenitor cells. Cell. 2001; 105: 43-55.
73. Oron-Karni V, Farhy C, Elgart M, et al. Dual requirement for Pax6 in retinal progenitor cells. Development. 2008; 135: 4037-47.
74. Yin VP, Poss KD. New regulators of vertebrate appendage regeneration. Curr Opin Genet Dev. 2008; 18: 381-6.
75. Tanaka EM. Cell differentiation and cell fate during urodele tail and limb regeneration. Curr Opin Genet Dev. 2003; 13: 497-501.
76. Stoick-Cooper CL, Moon RT, Weidinger G. Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine. Genes Dev. 2007; 21: 1292-315.
77. Gurtner GC, Werner S, Barrandon Y, et al. Wound repair and regeneration. Nature. 2008; 453: 314-21.
78. Bennicelli JL, Advani S, Schäfer BW, et al. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene. 1999; 18: 4348-56.
79. Abu Hatoum O, Gross-Mesilaty S, Breitschopf K, et al. Degradation of myogenic transcription factor MyoD by the ubiquitin pathway in vivo and in vitro: regulation by specific DNA binding. Mol Cell Biol. 1998; 18: 5670-7.
80. Cao Y, Wang C. The COOH-terminal transactivation domain plays a key role in regulating the in vitro and in vivo function of Pax3 homeodomain. J Biol Chem. 2000; 275: 9854-62.
81. Hollenbach AD, Sublett JE, McPherson CJ, et al. The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated repressor hDaxx. EMBO J. 1999; 18: 3702-11.
82. Muhr J, Andersson E, Persson M, et al. Groucho-mediated transcriptional repression establishes progenitor cell pattern and neuronal fate in the ventral neural tube. Cell. 2001; 104: 861-73.
83. Eberhard D, Jiménez G, Heavey B, et al. Transcriptional repression by Pax5 (BSAP) through interaction with corepressors of the Groucho family. EMBO J. 2000; 19: 2292-303.
84. Cai Y, Brophy PD, Levitan I, et al. Groucho suppresses Pax2 transactivation by inhibition of JNK-mediated phosphorylation. EMBO J. 2003; 22: 5522-9.
85. Sato H, Wang D, Kudo A. Dissociation of Pax-5 from KI and KII sites during kappa-chain gene rearrangement correlates with its association with the underphosphorylated form of retinoblastoma. J Immunol. 2001; 166: 6704-10.
86. Nitsch R, Di Palma T, Mascia A, et al. WBP-2, a WW domain binding protein, interacts with the thyroid-specific transcription factor Pax8. Biochem J. 2004; 377: 553-60.
87. White RB, Ziman MR. Genome-wide discovery of Pax7 target genes during development. Physiol Genomics. 2008; 33: 41-9.
88. Cai Y, Lechner MS, Nihalani D, et al. Phosphorylation of Pax2 by the c-Jun N-terminal kinase and enhanced Pax2-dependent transcription activation. J Biol Chem. 2002; 277: 1217-22.
89. Yan Q, Gong L, Deng M, et al. Sumoylation activates the transcriptional activity of Pax-6, an important transcription factor for eye and brain development. Proc Natl Acad Sci USA. 2010; 107: 21034-9.
90. Boutet SC, Disatnik MH, Chan LS, et al. Regulation of Pax3 by proteasomal degradation of monoubiquitinated protein in skeletal muscle progenitors. Cell. 2007; 130: 349-62.
91. Boutet SC, Biressi S, Iori K, et al. Taf1 regulates Pax3 protein by monoubiquitination in skeletal muscle progenitors. Mol Cell. 2010; 40: 749-61.
92. Cao X, Kambe F, Lu X, et al. Glutathionylation of two cysteine residues in paired domain regulates DNA binding activity of Pax-8. J Biol Chem. 2005; 280: 25901-6.
93. Jariel-Encontre I, Bossis G, Piechaczyk M. Ubiquitin-independent degradation of proteins by the proteasome. Biochim Biophys Acta. 2008; 1786: 153-77.
94. Chen JF, Tao Y, Li J, et al. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J Cell Biol. 2010; 190: 867-79.
95. Dey BK, Gagan J, Dutta A. miR-206 and -486 induce myoblast differentiation by downregulating Pax7. Mol Cell Biol. 2011; 31: 203-14.
96. Lin DI, Barbash O, Kumar KG, et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell. 2006; 24: 355-66.
97. Liu Y, Hedvat CV, Mao S, et al. The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Mol Cell Biol. 2006; 26: 3114-23.
98. Mouravlev A, Young D, During MJ. Phosphorylation-dependent degradation of transgenic CREB protein initiated by heterodimerization. Brain Res. 2007; 1130: 31-7.
99. Poizat C, Puri PL, Bai Y, et al. Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells. Mol Cell Biol. 2005; 25: 2673-87.
100. Spengler ML, Guo LW, Brattain MG. Phosphorylation mediates Sp1 coupled activities of proteolytic processing, desumoylation and degradation. Cell Cycle. 2008; 7: 623-30.
101. Wang Y, Liao M, Hoe N, et al. A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation. J Biol Chem. 2009; 284: 5671-84.
102. Christov C, Chrétien F, Abou-Khalil R, et al. Muscle satellite cells and endothelial cells: close neighbors and privileged partners. Mol Biol Cell. 2007; 18: 1397-409.
103. Joe AW, Yi L, Natarajan A, et al. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol. 2010; 12: 153-63.
104. Arnold L, Henry A, Poron F, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med. 2007; 204: 1057-69.
105. Rao TP, Kühl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res. 2010; 106: 1798-806.
106. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17: 9-26.
107. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008; 4: 68-75.
108. Snider L, Tapscott SJ. Emerging parallels in the generation and regeneration of skeletal muscle. Cell. 2003; 113: 811-12.
109. Takata H, Terada K, Oka H, et al. Involvement of Wnt4 signaling during myogenic proliferation and differentiation of skeletal muscle. Dev Dyn. 2007; 236: 2800-7.
110. Han XH, Jin YR, Seto M, et al. A WNT/{beta}-catenin signaling activator, R-spondin, plays positive regulatory roles during skeletal myogenesis. J Biol Chem. 2011; 286: 10649-59.
111. Kim CH, Neiswender H, Baik EJ, et al. Beta-catenin interacts with MyoD and regulates its transcription activity. Mol Cell Biol. 2008; 28: 2941-51.
112. + adult stem cells during muscle regeneration. Cell. 2003; 113: 841-52.
113. Shang YC, Wang SH, Xiong F, et al. Wnt3a signaling promotes proliferation, myogenic differentiation, and migration of rat bone marrow mesenchymal stem cells. Acta Pharmacol Sin. 2007; 28: 1761-74.
114. Perez-Ruiz A, Ono Y, Gnocchi VF, et al. Beta-Catenin promotes self-renewal of skeletal-muscle satellite cells. J Cell Sci. 2008; 121: 1373-82.
115. Le Grand F, Jones AE, Seale V, et al. Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. Cell Stem Cell. 2009; 4: 535-47.
116. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999; 284: 770-6.
117. Chiba S. Notch signaling in stem cell systems. Stem Cells. 2006; 24: 2437-47.
118. Kopan R, Nye JS, Weintraub H. The intracellular domain of mouse Notch: a constitutively activated repressor of myogenesis directed at the basic helix-loop-helix region of MyoD. Development. 1994; 120: 2385-96.
119. Vasyutina E, Lenhard DC, Wende H, et al. RBP-J (Rbpsuh) is essential to maintain muscle progenitor cells and to generate satellite cells. Proc Natl Acad Sci USA. 2007; 104: 4443-8.
120. Schuster-Gossler K, Cordes R, Gossler A. Premature myogenic differentiation and depletion of progenitor cells cause severe muscle hypotrophy in Delta1 mutants. Proc Natl Acad Sci USA. 2007; 104: 537-42.
121. Sun D, Li H, Zolkiewska A. The role of Delta-like 1 shedding in muscle cell self-renewal and differentiation. J Cell Sci. 2008; 121: 3815-23.
122. Conboy IM, Rando TA. The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. Dev Cell. 2002; 3: 397-409.
123. Kitzmann M, Bonnieu A, Duret C, et al. Inhibition of Notch signaling induces myotube hypertrophy by recruiting a subpopulation of reserve cells. J Cell Physiol. 2006; 208: 538-48.
124. Furutani Y, Umemoto T, Murakami M, et al. Role of endogenous TGF-β family in myogenic differentiation of C2C12 cells. J Cell Biochem. 2011; 112: 614-24.
125. Carlson ME, Hsu M, Conboy IM. Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature. 2008; 454: 528-32.
126. Droguett R, Cabello-Verrugio C, Santander C, et al. TGF-beta receptors, in a Smad-independent manner, are required for terminal skeletal muscle differentiation. Exp Cell Res. 2010; 316: 2487-503.
127. Patterson SE, Bird NC, Devoto SH. BMP regulation of myogenesis in zebrafish. Dev Dyn. 2010; 239: 806-17.
128. Amthor H, Otto A, Macharia R, et al. Myostatin imposes reversible quiescence on embryonic muscle precursors. Dev Dyn. 2006; 235: 672-80.
129. Siriett V, Salerno MS, Berry C, et al. Antagonism of myostatin enhances muscle regeneration during sarcopenia. Mol Ther. 2007; 15: 1463-70.
130. Li X, Nie F, Yin Z, et al. Enhanced hyperplasia in muscles of transgenic zebrafish expressing Follistatin1. Sci China Life Sci. 2011; 54: 159-65.
131. Iezzi S, Di Padova M, Serra C, et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell. 2004; 6: 673-84.
132. Pisconti A, Brunelli S, Di Padova M, et al. Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion. J Cell Biol. 2006; 172: 233-44.
133. Vaidya TB, Rhodes SJ, Taparowski EJ, et al. Fibroblast growth factor and transforming growth factor fl repress transcription of the myogenic regulatory gene MyoD1. Mol Cell Biol. 1989; 9: 3576-9.
134. Martin JF, Li L, Olson EN. Repression of myogenin function by TGF-beta 1 is targeted at the basic helix-loop-helix motif and is independent of E2A products. J Biol Chem. 1992; 267: 10956-60.
135. Li X, McFarland DC, Velleman SG. Transforming growth factor-beta1-induced satellite cell apoptosis in chickens is associated with beta1 integrin-mediated focal adhesion kinase activation. Poult Sci. 2009; 88: 1725-34.
136. Ugarte G, Brandan E. Transforming growth factor beta (TGF-beta) signaling is regulated by electrical activity in skeletal muscle cells. TGF-beta type I receptor is transcriptionally regulated by myotube excitability. J Biol Chem. 2006; 281: 18473-81.
137. Droguett R, Cabello-Verrugio C, Riquelme C, et al. Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol. 2006; 25: 332-41.
138. Amthor H, Nicholas G, McKinnell I, et al. Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol. 2004; 270: 19-30.
139. Lee SJ, Lee YS, Zimmers TA, et al. Regulation of muscle mass by follistatin and activins. Mol Endocrinol. 2010; 24: 1998-2008.
140. Tkachenko E, Rhodes JM, Simons M. Syndecans: new kids on the signaling block. Circ Res. 2005; 96: 488-500.
141. Couchman JR Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol. 2003; 4: 926-37.
142. Rapraeger AC. Syndecan-regulated receptor signaling. J Cell Biol. 2000; 149: 995-8.
143. Cornelison DD, Wilcox-Adelman SA, Goetinck PF, et al. Essential and separable roles for Syndecan-3 and Syndecan-4 in skeletal muscle development and regeneration. Genes Dev. 2004; 18: 2231-6.
144. Pisconti A, Cornelison DD, Olguín HC, et al. Syndecan-3 and Notch cooperate in regulating adult myogenesis. J Cell Biol. 2010; 190: 427-41.
145. Casar JC, Cabello-Verrugio C, Olguin H, et al. Heparan sulfate proteoglycans are increased during skeletal muscle regeneration: requirement of Syndecan-3 for successful fiber formation. J Cell Sci. 2004; 117: 73-84.
146. Jones NC, Fedorov YV, Rosenthal RS, et al. ERK1/2 is required for myoblast proliferation but is dispensable for muscle gene expression and cell fusion. J Cell Physiol. 2001; 186: 104-15.
147. Fuentealba L, Carey DJ, Brandan E. Antisense inhibition of Syndecan-3 expression during skeletal muscle differentiation accelerates myogenesis through a basic fibroblast growth factor-dependent mechanism. J Biol Chem. 1999; 274: 37876-84.
148. Olwin BB, Hauschka SD. Identification of the fibroblast growth factor receptor of Swiss 3T3 cells and mouse skeletal muscle myoblasts. Biochemistry. 1986; 25: 3487-92.
149. Acharyya S, Sharma SM, Cheng AS, et al. TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in Duchenne muscular dystrophy. PLoS One. 2010; 5: e12479.
150. Valerio A, Cardile A, Cozzi V, et al. TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest. 2006; 116: 2791-8.
151. Li YP. TNF-alpha is a mitogen in skeletal muscle. Am J Physiol Cell Physiol. 2003; 285: C370-6.
152. Mozzetta C, Consalvi S, Saccone V, et al. Selective control of Pax7 expression by TNF-activated p38α/polycomb repressive complex 2 (PRC2) signaling during muscle satellite cell differentiation. Cell Cycle. 2011; 10: 191-8.
153. Palacios D, Mozzetta C, Consalvi S, et al. TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell. 2010; 7: 455-69.
154. Jones NC, Tyner KJ, Nibarger L, et al. The p38alpha/beta MAPK functions as a molecular switch to activate the quiescent satellite cell. J Cell Biol. 2005; 169: 105-16.
155. Cohn RD, Campbell KP. Molecular basis of muscular dystrophies. Muscle Nerve. 2000; 23: 1456-71.
156. Emery AEThe muscular dystrophies. Lancet. 2002; 359: 687-95.
157. Rüegg MA, Glass DJ. Molecular mechanisms and treatment options for muscle wasting diseases. Annu Rev Pharmacol Toxicol. 2011; 51: 373-95.
158. Scimè A, Rudnicki MA. Anabolic potential and regulation of the skeletal muscle satellite cell populations. Curr Opin Clin Nutr Metab Care. 2006; 9: 214-19.
159. Sacco A, Mourkioti F, Tran R, et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell. 2010; 143: 1059-71.
160. Decary S, Hamida CB, Mouly V, et al. Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscul Disord. 2000; 10: 113-20.
161. Decary S, Mouly V, Hamida CB, et al. Replicative potential and telomere length in human skeletal muscle: implications for satellite cell-mediated gene therapy. Hum Gene Ther. 1997; 8: 1429-38.
162. Cossu G, Mavilio F. Myogenic stem cells for the therapy of primary myopathies: wishful thinking or therapeutic perspective? J Clin Invest. 2000; 105: 1669-74.
163. Kapsa R, Kornberg AJ, Byrne E. Novel therapies for Duchenne muscular dystrophy. Lancet Neurol. 2003; 2: 299-310.
164. Asakura A, Hirai H, Kablar B, et al. Increased survival of muscle stem cells lacking the MyoD gene after transplantation into regenerating skeletal muscle. Proc Natl Acad Sci USA. 2007; 104: 16552-7.